July 17, 2025 | Aclymate, Carbon Emissions, Carbon footprint, Hybrid Events, Hybrid meetings, Impetus Digital, Pharma meetings, Sustainability, carbon neutral, green pharma, pharma vvents, reduce carbon, sustainable pharma
Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.
In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!
Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Mike Waldron, CEO and Co-Founder of Propel VR, discusses how virtual reality (VR) and augmented reality (AR) can be leveraged in the healthcare industry, including specific applications of VR/AR for…
Ariel Garten, Founder & Chief Evangelism Officer at Muse, explores many exciting topics such as the idea of whether art and beauty can be broken down into biological codes, the…
Dr. Jason Cross, Co-founder & Chief Strategy Officer at Rymedi, dives into Connected Health, including how it can be used to expand access to high-quality healthcare, current barriers to its…
Caitlin Wagner, Associate Marketing Director at Pharming, shares her expertise on innovative patient engagement strategies, including the roles of mobile apps and social media, the impact of the COVID-19 pandemic…
Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his…
Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac…
Tom Hsu, VP of Specialty Medicine at Bayer Canada, talks about how he got to where he is today and his experience working for Bayer in China and how that…
Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work…
Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, talks about everything from his personal health journey to his…
Esther Schorr, Co-founder and Chief Operating Officer of Patient Power LLC, discusses non-linear journey to patient education and Patient Power’s mission to empower patients and their loved ones to take…


